Cargando…

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment

Antisense oligonucleotides (AOs) are currently the most promising therapeutic intervention for Duchenne muscular dystrophy (DMD). AOs modulate dystrophin pre-mRNA splicing, thereby specifically restoring the dystrophin reading frame and generating a truncated but semifunctional dystrophin protein. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Betts, Corinne, Saleh, Amer F, Arzumanov, Andrey A, Hammond, Suzan M, Godfrey, Caroline, Coursindel, Thibault, Gait, Michael J, Wood, Matthew JA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438601/ https://www.ncbi.nlm.nih.gov/pubmed/23344180 http://dx.doi.org/10.1038/mtna.2012.30

Ejemplares similares

Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells
por: Lehto, Taavi, et al.
Publicado: (2014)

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
por: Gait, Michael J., et al.
Publicado: (2019)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
por: Betts, Corinne A, et al.
Publicado: (2019)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts
por: Lee, Joshua, et al.
Publicado: (2018)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
por: Blain, Alison M., et al.
Publicado: (2018)

Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD
por: Akpulat, Ugur, et al.
Publicado: (2018)

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2015)

Skipping Multiple Exons to Treat DMD—Promises and Challenges
por: Aslesh, Tejal, et al.
Publicado: (2018)

Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
por: Järver, Peter, et al.
Publicado: (2012)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle
por: Ivanova, Gabriela D., et al.
Publicado: (2008)

Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention
por: Tyagi, Rahul, et al.
Publicado: (2019)

Prime editing strategies to mediate exon skipping in DMD gene
por: Happi Mbakam, Cedric, et al.
Publicado: (2023)

Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient
por: Saito, Takashi, et al.
Publicado: (2010)

Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot
por: Suzuki, Hitoshi, et al.
Publicado: (2016)

Synthesis and Splice-Redirecting Activity of Branched, Arginine-Rich Peptide Dendrimer Conjugates of Peptide Nucleic Acid Oligonucleotides
por: Saleh, Amer F., et al.
Publicado: (2010)

Synthesis and Exon-Skipping Properties of a 3′-Ursodeoxycholic Acid-Conjugated Oligonucleotide Targeting DMD Pre-mRNA: Pre-Synthetic versus Post-Synthetic Approach
por: Marchesi, Elena, et al.
Publicado: (2021)

Novel Exon-Skipping Therapeutic Approach for the DMD Gene Based on Asymptomatic Deletions of Exon 49
por: Abaji, Mario, et al.
Publicado: (2022)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

What Can We Learn From Clinical Trials of Exon Skipping for DMD?
por: Lu, Qi-long, et al.
Publicado: (2014)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
por: Gapinske, Michael, et al.
Publicado: (2023)

Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
por: Kim, Young Jin, et al.
Publicado: (2022)

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
por: Yin, HaiFang, et al.
Publicado: (2013)

Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models
por: Saoudi, Amel, et al.
Publicado: (2023)

Efficacy of exon-skipping therapy for DMD cardiomyopathy with mutations in actin binding domain 1
por: Shiba, Naoko, et al.
Publicado: (2023)

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
por: Yin, HaiFang, et al.
Publicado: (2020)

Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides
por: Turner, John J., et al.
Publicado: (2005)

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy
por: Marchesi, Elena, et al.
Publicado: (2022)

Cell penetrating peptide conjugates of steric block oligonucleotides()
por: Lebleu, Bernard, et al.
Publicado: (2008)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches
por: Lorain, Stéphanie, et al.
Publicado: (2013)

Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy
por: Okubo, Mariko, et al.
Publicado: (2020)

Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping
por: Wang, Peipei, et al.
Publicado: (2022)

Prevention of early-onset cardiomyopathy in Dmd exon 52–54 deletion mice by CRISPR-Cas9-mediated exon skipping
por: Rok, Matthew, et al.
Publicado: (2023)

Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
por: Järver, Peter, et al.
Publicado: (2015)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
por: Miskew Nichols, Bailey, et al.
Publicado: (2016)

Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse
por: Wang, Derek W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6gbri3nkrs5jv2dal4vbk4p584